Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip, Byoung Chul Cho, Valentín García‐Gutiérrez, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 805-816
Open Access | Times Cited: 25

Showing 25 citing articles:

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer
Md Nazmul Hasan, Misako Nagasaka
Expert Review of Respiratory Medicine (2025)
Closed Access | Times Cited: 1
Liquid biopsy in lung cancer
Susumu KITAGAWA, Masahiro Seike
Japanese Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.2
Lyudmila Bazhenova, Nofisat Ismaila, Fawzi Abu Rous, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 5
Actualités dans le cancer broncho-pulmonaire : traitements médicaux
Gérard Zalcman
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Leptomeningeal Disease in Lung Cancer: An Unmet Need That Needs to Be Met
Hossein Borghaei, Tony Mok
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 17-19
Closed Access
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)
Cesare Gridelli, Tony Mok, Pasi A. Jänne, et al.
Lung Cancer (2025) Vol. 201, pp. 108100-108100
Closed Access
Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations
Jamie Feng, Katrina Hueniken, Zhen Jason Fan, et al.
Lung Cancer (2025), pp. 108452-108452
Closed Access
Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2042-2042
Open Access
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
Dwight H. Owen, Nofisat Ismaila, Amith Ahluwalia, et al.
Journal of Clinical Oncology (2025)
Closed Access
New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib
Paolo Maione, Vincenzo Palma, Giuseppina Pucillo, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 847-847
Open Access
Lung Cancer: Targeted Therapy in 2025
Nicole Bouchard, Nathalie Daaboul
Current Oncology (2025) Vol. 32, Iss. 3, pp. 146-146
Open Access
Novel strategies for rare oncogenic drivers in non-small-cell lung cancer: An update from the 2024 Annual ESMO meeting
Tijmen J.W.T. van der Wel, Adrianus J. de Langen
Lung Cancer (2025), pp. 108490-108490
Closed Access
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
Kaibo Ding, Zhongsheng Peng, Dujiang Liu, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
EGFR-mutated NSCLC: A roadmap to treatment sequences
Nicolas Girard
Med (2024) Vol. 5, Iss. 9, pp. 1044-1047
Closed Access | Times Cited: 2
The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC
Fatemeh Ardeshir‐Larijani, Suresh S. Ramalingam
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 11, pp. 767-768
Closed Access | Times Cited: 1
PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
T. Nishimura, Hajime Fujimoto
Annals of Oncology (2024)
Closed Access | Times Cited: 1
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
Se‐Hoon Lee, Jessica Menis, T.M. Kim, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 103996-103996
Closed Access | Times Cited: 1
Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review
Vivek Podder, Tulika Ranjan, M. Gowda, et al.
Current Neurology and Neuroscience Reports (2024) Vol. 25, Iss. 1
Closed Access | Times Cited: 1
Prediction of EGFR-TP53 genes co-mutations in patients with lung adenocarcinoma (LUAD) by 18F-FDG PET/CT radiomics
Shuheng Li, Yujing Hu, Congna Tian, et al.
Clinical & Translational Oncology (2024)
Closed Access
Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR
Jacques Cadranel, Vincent Fallet, Simon Baldacci, et al.
Revue des Maladies Respiratoires Actualités (2024) Vol. 16, Iss. 2, pp. 2S194-2S214
Closed Access
Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto
Enriqueta Felip, B.C. Cho, Danny Nguyen, et al.
Annals of Oncology (2024)
Closed Access
Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases
Vesna Ćeriman Krstić, Ivan Soldatović, Natalija Samardžić, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 12, pp. 13431-13442
Open Access
EGFR, TP53, and CUL3 Triple Mutation in Non‐Small Cell Lung Cancer and its Potentially Poor Prognosis: A Case Report and Database Analysis
Hiroto Hatano, Tatsuya Yoshida, Ryoko Inaba Higashiyama, et al.
Thoracic Cancer (2024)
Open Access
Page 1

Scroll to top